Clinical Trials

805 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT03663205 2025-02-04

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

334 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03924986 2025-01-31

RATIONALE-309

263 enrolled 19 charts

Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT04732494 2025-01-31

AdvanTIG-203

125 enrolled 25 charts

Esophageal Squamous Cell Carcinoma

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

71 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Completed

216 enrolled 20 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03419897 2024-10-26

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

249 enrolled 24 charts

Carcinoma, Hepatocellular

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

512 enrolled 27 charts

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

77 enrolled 20 charts

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase 1/2 Completed

111 enrolled 22 charts

Carcinoma, Carcinoma, Hepatocellular

NCT04004221 2024-10-26

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

113 enrolled 15 charts

Genitourinary

Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1/2 Completed

300 enrolled 23 charts

Other solid neoplasm

Advanced Solid Tumors

NCT04952597 2024-10-26

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

126 enrolled 19 charts

Limited Stage Small Cell Lung Cancer

NCT03432598 2024-10-23

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

54 enrolled

Lung Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

30 enrolled

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

118 enrolled

Locally Advanced Rectal Cancer

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

56 enrolled